PÃ¥l Berg-Hansen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9891270/publications.pdf

Version: 2024-02-01

23 papers 389 citations

840776 11 h-index 18 g-index

24 all docs

24 docs citations

24 times ranked 717 citing authors

#	Article	IF	Citations
1	Stereotyped Bâ€eell responses are linked to IgG constant region polymorphisms in multiple sclerosis. European Journal of Immunology, 2022, 52, 550-565.	2.9	10
2	Sensor-based gait analyses of the six-minute walk test identify qualitative improvement in gait parameters of people with multiple sclerosis after rehabilitation. Journal of Neurology, 2022, 269, 3723-3734.	3.6	6
3	The influence of socioeconomic factors on access to disease modifying treatment in a Norwegian multiple sclerosis cohort. Multiple Sclerosis and Related Disorders, 2022, 61, 103759.	2.0	3
4	Exploring Retinal Blood Vessel Diameters as Biomarkers in Multiple Sclerosis. Journal of Clinical Medicine, 2022, 11, 3109.	2.4	3
5	Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 1859-1870.	3.0	14
6	Fatigue in multiple sclerosis is associated with socioeconomic factors. Multiple Sclerosis and Related Disorders, 2022, 64, 103955.	2.0	5
7	The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression. Journal of Neurology, 2021, 268, 1330-1341.	3.6	17
8	High prevalence of fatigue in contemporary patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732199982.	1.0	18
9	Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry. Frontiers in Neurology, 2021, 12, 693017.	2.4	45
10	Maternal education has significant influence on progression in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 53, 103052.	2.0	6
11	No significant differences in absenteeism or academic achievements in a Norwegian multiple sclerosis case control study. Multiple Sclerosis and Related Disorders, 2021, 54, 103141.	2.0	2
12	Hospitalization following influenza infection and pandemic vaccination in multiple sclerosis patients: a nationwide population-based registry study from Norway. European Journal of Epidemiology, 2020, 35, 355-362.	5.7	22
13	Prevalence of multiple sclerosis in rural and urban districts in Telemark county, Norway. Multiple Sclerosis and Related Disorders, 2020, 45, 102352.	2.0	8
14	LesionQuant for Assessment of MRI in Multiple Sclerosis—A Promising Supplement to the Visual Scan Inspection. Frontiers in Neurology, 2020, 11, 546744.	2.4	9
15	The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521731990129.	1.0	18
16	No differential gene expression for CD4+ T cells of MS patients and healthy controls. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731985690.	1.0	9
17	Quantitative proteomic analyses of CD4+ and CD8+ T cells reveal differentially expressed proteins in multiple sclerosis patients and healthy controls. Clinical Proteomics, 2019, 16, 19.	2.1	24
18	Restriction spectrum imaging of white matter and its relation to neurological disability in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 687-698.	3.0	8

#	Article	IF	CITATIONS
19	Increased DNA methylation of SLFN12 in CD4+ and CD8+ T cells from multiple sclerosis patients. PLoS ONE, 2018, 13, e0206511.	2.5	37
20	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain, 2015, 138, 632-643.	7.6	54
21	Prevalence of multiple sclerosis among immigrants in Norway. Multiple Sclerosis Journal, 2015, 21, 695-702.	3.0	43
22	Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general. Journal of Neuroimmunology, 2014, 274, 174-179.	2.3	7
23	Calprotectin levels in the cerebrospinal fluid reflect disease activity in multiple sclerosis. Journal of Neuroimmunology, 2009, 216, 98-102.	2.3	21